OverviewSuggest Edit

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.
HQIllkirch, FR

Latest Updates

Employees (est.) (Aug 2020)136(+4%)
Job Openings5
Share Price (Sept 2020)€1.2 (+2%)
Cybersecurity ratingAMore

Key People/Management at Transgene

Juan Pedro R. Serrate

Juan Pedro R. Serrate


Transgene Office Locations

Transgene has offices in Illkirch, Lyon, Boston and Shanghai
Shanghai, CN
Rm 508, Building 2 4633, Pusan Road Kangqiao Industrial Park, Pudong Shanghai
Lyon, FR
321 Avenue Jean Jaurès
Boston, US
201 Washington St
Show all (4)

Transgene Financials and Metrics

Transgene Revenue

Market capitalization (28-Sept-2020)


Closing stock price (28-Sept-2020)

Transgene's current market capitalization is €102.8 m.
Show all financial metrics

Transgene Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Transgene Online and Social Media Presence

Embed Graph

Transgene News and Updates

BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors

LUND, Sweden and STRASBOURG, France, Dec. 11, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris:...

CTIBiotech - Transgene Collaboration for Cancer Research

CTIBioTumour: Human Tumours Produced by 3D Bioprinting to Accelerate the Development of New Cancer Therapies

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

LUND, Sweden and STRASBOURG, France, March 26, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer and Transgene (Euronext Paris: TNG), a biotech company that designs ...

Gene Therapy Market to Set Phenomenal Growth from 2018 to 2026 Estimated by Global Top Players GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA

#Summary: Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twi…
Show more

Transgene Frequently Asked Questions

  • Who are Transgene key executives?

    Transgene's key executives are Juan Pedro R. Serrate.

  • How many employees does Transgene have?

    Transgene has 136 employees.

  • Who are Transgene competitors?

    Competitors of Transgene include Magenta Therapeutics, Synthace and ProtoKinetix.

  • Where are Transgene offices?

    Transgene has offices in Illkirch, Lyon, Boston and Shanghai.

  • How many offices does Transgene have?

    Transgene has 4 offices.